Neuroendocrine carcinoma metastatic – Basic Information

Go back

Metastatic neuroendocrine carcinoma occurs when cancer cells originating from specialized neuroendocrine cells break away from their original location and spread to distant parts of the body, most commonly the liver, lungs, and lymph nodes. Understanding this condition is essential for patients and families navigating the challenges of diagnosis, treatment, and living with a cancer that often develops slowly over many years.

What is Metastatic Neuroendocrine Carcinoma?

Neuroendocrine carcinoma develops in specialized cells found throughout the body. These remarkable cells combine the characteristics of nerve cells, which send and receive signals from the brain, and endocrine cells, which produce hormones that regulate various body functions. When these cells are functioning normally, they help control important processes like digestion, breathing, and other vital activities.

When neuroendocrine cells begin to divide and multiply uncontrollably, they form tumors. These tumors can develop in many different organs, though they are most commonly found in the gastrointestinal tract, lungs, and pancreas. Once the cancer becomes metastatic, it means that cancer cells have broken away from the original tumor site and traveled through the bloodstream or lymphatic system (the network of vessels and tissues that help fight infection) to create new tumors in distant organs or tissues.[1]

The most frequent sites where metastatic neuroendocrine cancer spreads include the liver, lungs, and lymph nodes. In many cases, both lobes of the liver may be affected when the cancer reaches this organ. The liver is particularly vulnerable to metastasis from neuroendocrine tumors, especially those originating in the gastrointestinal tract.[4]

These cancers are also known as neuroendocrine tumors (NETs) or, in some cases, carcinoid tumors, though this older term is less commonly used today. Most neuroendocrine tumors are malignant, meaning they have the potential to grow and spread to other parts of the body.[2]

Epidemiology: How Common Is This Disease?

Neuroendocrine tumors are considered rare cancers. Worldwide, they affect approximately 6 in every 100,000 people. Despite their rarity, more people are being diagnosed with these tumors now than in previous years. This increase is likely due to improved diagnostic techniques and imaging technologies that can detect these cancers more quickly and accurately.[3]

While anyone can develop neuroendocrine tumors, they are quite rare in children, teenagers, and young adults. Most people who receive this diagnosis are between the ages of 50 and 60. This age pattern suggests that these tumors typically take many years to develop and become noticeable.[3]

A particularly concerning statistic reveals that approximately 60% of neuroendocrine tumor patients already have Stage 4 disease (meaning the cancer has spread to distant parts of the body) by the time they receive a correct diagnosis. This delayed diagnosis often occurs because the symptoms can be vague and easily confused with other, less serious conditions.[1]

The location where the primary tumor originates significantly affects the likelihood of metastasis. For example, while the appendix is the most common location for midgut carcinoid tumors, these rarely spread to the liver. In contrast, neuroendocrine pancreatic tumors show varying rates of liver metastasis depending on their type, with insulinomas rarely causing liver spread, while more than 50% of patients with other types of pancreatic neuroendocrine tumors already have liver metastases by the time of diagnosis.[4]

Causes: What Triggers This Cancer?

The exact causes of metastatic neuroendocrine cancer remain largely unknown to researchers. Scientists understand that these cancers develop when neuroendocrine cells begin to divide and multiply uncontrollably, eventually forming tumors that can affect the organs where these cells are located. However, what triggers this abnormal cell growth in the first place is not yet clear.[3]

The process of metastasis begins when cancer cells break away from the original (primary) tumor. These rogue cells then travel through the body’s circulatory systems—either through blood vessels or through the lymphatic system. Once they reach a new location, they can settle in and begin forming secondary tumors in distant organs or tissues. This spread to distant sites is what defines metastatic cancer.[1]

Because these tumors typically grow very slowly, the body may have been fighting them for years before they become large enough to cause symptoms or be detected through medical tests. This slow growth pattern means that by the time someone feels unwell enough to seek medical attention, the cancer may have already spread to other organs.[5]

⚠️ Important
The slow-growing nature of neuroendocrine tumors means that symptoms may develop gradually over many years. People often dismiss early warning signs or attribute them to other health issues or simply getting older. This makes regular check-ups and paying attention to persistent symptoms particularly important, especially if you have known risk factors for these cancers.

Risk Factors: Who Is More Likely to Develop This Cancer?

While the exact causes remain unclear, researchers have identified several factors that may increase a person’s likelihood of developing neuroendocrine tumors. It’s important to understand that having one or more risk factors doesn’t guarantee you will develop this cancer, and some people diagnosed with these tumors have no known risk factors at all.[3]

Inherited Genetic Syndromes

The strongest known risk factors for neuroendocrine tumors involve inherited genetic conditions. Some individuals carry genetic mutations (changes in their DNA) that make them more susceptible to developing these cancers. The most important hereditary conditions include:[1][3]

  • Multiple endocrine neoplasia (MEN): This condition causes overactive tumors to form in various organs and glands of the endocrine system. Type 1 (MEN1) is the most common cancer syndrome associated with neuroendocrine tumors. MEN type 2 also increases risk.
  • Von Hippel-Lindau syndrome: This inherited disorder can lead to various types of tumors and cysts throughout the body, including neuroendocrine tumors.
  • Neurofibromatosis type 1 (NF1) syndrome: This genetic condition causes tumors to form on nerve tissue and can increase the risk of developing neuroendocrine cancers.
  • Medullary thyroid cancer (MTC), which may be inherited and associated with increased risk.

Other Medical Conditions

Certain medical conditions that affect the stomach’s ability to produce stomach acid have been linked to an increased risk of gastrointestinal neuroendocrine tumors. These include:[6]

  • Atrophic gastritis: A condition where the stomach lining becomes inflamed and damaged over time
  • Pernicious anemia: A type of anemia caused by the body’s inability to absorb vitamin B12
  • Zollinger-Ellison syndrome: A rare condition where tumors cause the stomach to produce too much acid

Delayed Diagnosis as a Contributing Factor

While not a traditional risk factor for developing the disease initially, delayed diagnosis significantly increases the risk that a neuroendocrine tumor will have spread by the time it is detected. Because symptoms can be vague and easily mistaken for other conditions, many patients experience delays in receiving an accurate diagnosis, allowing time for metastasis to occur.[1]

Symptoms: How Does Metastatic Neuroendocrine Cancer Affect Patients?

The symptoms of metastatic neuroendocrine cancer can vary significantly depending on where the tumors are located, how large they’ve grown, and whether they produce hormones. Many of these tumors don’t cause any symptoms in their early stages, which is one reason why they often aren’t discovered until they’ve already spread.[2]

General Symptoms

When tumors grow large enough to affect nearby organs or when they spread to distant sites, patients may experience general symptoms such as:[1][3]

  • Fatigue: Persistent tiredness and weakness that doesn’t improve with rest
  • Unexplained weight loss: Significant weight loss occurring over a relatively short period without intentional dieting
  • Abdominal pain: Discomfort or pain in the belly area, especially common with gastrointestinal neuroendocrine tumors
  • Nausea and vomiting: Feeling sick to your stomach or actually vomiting
  • Diarrhea: Frequent loose or watery bowel movements

Respiratory Symptoms

When neuroendocrine tumors affect the lungs or spread to the respiratory system, patients may experience:[1]

  • Persistent cough that doesn’t go away
  • Wheezing or difficulty breathing
  • Shortness of breath
  • In some cases, coughing up blood

Hormone-Related Symptoms

Some neuroendocrine tumors are classified as “functional,” meaning they produce and release hormones into the bloodstream. These hormones can cause a variety of symptoms depending on which type is being overproduced. About half of all neuroendocrine tumors are “non-functioning,” meaning patients don’t experience hormone-related symptoms.[4]

When tumors do produce hormones, patients may experience:[1]

  • Flushing: Sudden reddening of the face and upper body, often accompanied by a feeling of warmth
  • Changes in blood sugar levels, which can cause symptoms ranging from shakiness and sweating (low blood sugar) to increased thirst and frequent urination (high blood sugar)
  • Severe diarrhea related to hormone production
  • Skin changes, including rashes

Carcinoid Syndrome

A specific group of symptoms called carcinoid syndrome may occur if the tumor spreads to the liver or other parts of the body. This syndrome happens when tumor cells release certain hormones and chemical substances directly into the bloodstream. It typically includes facial flushing, diarrhea, and sometimes wheezing or rapid heartbeat.[6]

It’s crucial to remember that experiencing these symptoms doesn’t automatically mean you have cancer. Many of these signs can be caused by far less serious conditions. However, if you’re experiencing persistent symptoms that don’t improve or that concern you, it’s important to talk to a healthcare provider who can properly evaluate your situation.[3]

Prevention: Can Metastatic Neuroendocrine Cancer Be Prevented?

Because the exact causes of neuroendocrine tumors remain unknown, there are no guaranteed ways to prevent them from developing. However, there are steps that may help reduce risk or catch these cancers earlier when they’re more treatable.

Genetic Counseling and Testing

For individuals with a family history of neuroendocrine tumors or known inherited syndromes like Multiple Endocrine Neoplasia (MEN1 or MEN2), Von Hippel-Lindau syndrome, or Neurofibromatosis Type 1, genetic counseling and testing can be valuable. Understanding your genetic risk allows for earlier and more frequent screening, potentially catching tumors before they spread.[1]

If you have a family history of these conditions, talk to your healthcare provider about whether genetic testing might be appropriate for you. This information can help guide decisions about screening frequency and methods.[3]

Early Detection Through Awareness

While not prevention in the traditional sense, recognizing symptoms early and seeking prompt medical attention can help prevent the progression to metastatic disease. Being aware of the warning signs and not dismissing persistent symptoms as minor issues is crucial. Because 60% of patients are already at Stage 4 when correctly diagnosed, improving awareness and reducing diagnostic delays could significantly impact outcomes.[1]

Managing Risk Factors

For conditions that increase risk, such as atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndrome, working with your healthcare provider to manage these conditions properly may help. Regular monitoring when these conditions are present allows for earlier detection if tumors do develop.[6]

Pathophysiology: How Does This Cancer Change Normal Body Functions?

Understanding how metastatic neuroendocrine cancer affects the body requires looking at both the mechanical impact of tumor growth and the biochemical changes that occur, particularly when tumors produce hormones.

The Metastatic Process

The spread of neuroendocrine cancer involves a complex series of biological events. Cancer cells must first break away from the primary tumor—this requires them to overcome the normal cellular adhesion mechanisms that usually keep cells in place. Once free, these cells enter either the bloodstream or the lymphatic system, where they travel throughout the body.[1]

Not all traveling cancer cells successfully form new tumors. Most die during the journey or are destroyed by the immune system. However, some manage to exit the circulation at a distant site, attach to tissues in a new location, and begin multiplying to form secondary tumors (metastases). The liver is particularly vulnerable to this process for neuroendocrine tumors originating in the gastrointestinal tract because blood from the digestive system flows directly to the liver through the portal vein.[4]

Mechanical Effects of Tumor Growth

As tumors grow, they physically disrupt normal organ function. In the liver, metastatic tumors can replace healthy liver tissue, affecting the organ’s ability to perform its many essential functions, including filtering blood, producing proteins, and metabolizing drugs. When tumors are extensive, they can cause the liver to enlarge significantly, leading to abdominal discomfort and a distended appearance.[5]

In the gastrointestinal tract, growing tumors can narrow or block passages, interfering with digestion and the movement of food through the intestines. This can lead to pain, changes in bowel habits, and difficulty eating normal amounts of food.[9]

Hormonal and Biochemical Changes

Functional neuroendocrine tumors produce hormones and other biologically active substances. When a tumor spreads to the liver, these hormones can be released directly into the general circulation without being processed by the liver first, leading to more pronounced symptoms. This is why carcinoid syndrome and other hormone-related symptom clusters often don’t appear until liver metastases develop.[6]

Different types of neuroendocrine tumors produce different hormones, leading to varying symptom patterns. Some produce insulin, causing dangerously low blood sugar levels. Others produce substances that affect digestion, blood pressure, or other vital functions. The inappropriate release of these hormones disrupts the body’s normal regulatory systems.[4]

Impact on Blood and Nutrition

Metastatic neuroendocrine cancer can lead to anemia, as one patient discovered when blood tests revealed she was severely anemic before her diagnosis. This occurs through multiple mechanisms: tumors may bleed slowly, the cancer may interfere with the body’s ability to produce red blood cells, or the overall burden of disease may affect nutritional status.[5]

The cancer and its effects on the digestive system can also lead to malabsorption of nutrients, contributing to weight loss, fatigue, and overall decline in health. When liver function is compromised by metastatic disease, this affects the body’s ability to process vitamins, produce essential proteins, and maintain proper metabolic balance.[4]

⚠️ Important
The complex nature of metastatic neuroendocrine cancer means that treatment often requires a multidisciplinary team of specialists working together. This typically includes oncologists, endocrinologists, surgeons, radiologists, and other healthcare professionals who can address the various ways this cancer affects the body. Don’t hesitate to ask questions about how your specific cancer is impacting your body systems and what can be done to manage these effects.

Slow Growth Characteristics

One distinctive characteristic of many neuroendocrine tumors is their relatively slow growth rate compared to other cancers. While this can mean better long-term survival prospects, it also means that tumors may be present and growing for many years before causing noticeable symptoms. The body may develop compensatory mechanisms during this slow progression, which is why some patients with extensive metastatic disease may not feel as ill as might be expected given the extent of their cancer.[4]

Ongoing Clinical Trials on Neuroendocrine carcinoma metastatic

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Denmark
  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    2 1 1 1
    Denmark
  • A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    France
  • Study of AdVince (Modified Adenovirus) Treatment Through Hepatic Artery Injection in Patients with Advanced Neuroendocrine Neoplasms

    Not recruiting

    1 1 1
    Investigated diseases:
    Sweden
  • Study of Durvalumab, Carboplatin and Etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Italy

References

https://neuroendocrine.org.au/what-are-nets/metastatic-neuroendocrine-cancer/

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/symptoms-causes/syc-20354132

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.ncbi.nlm.nih.gov/books/NBK6993/

https://www.mdanderson.org/cancerwise/neuroendocrine-tumors–9-things-to-know.h00-159379578.html

https://www.cancer.gov/types/gi-neuroendocrine-tumors/patient/gi-neuroendocrine-treatment-pdq

https://pmc.ncbi.nlm.nih.gov/articles/PMC9100271/

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/understanding-neuroendocrine-cancer/

https://www.dukehealth.org/treatments/cancer/neuroendocrine-tumors

FAQ

Why is metastatic neuroendocrine cancer often diagnosed at an advanced stage?

Metastatic neuroendocrine cancer is frequently diagnosed at Stage 4 because these tumors typically grow very slowly and may not cause symptoms until they become quite large or spread to other organs. The symptoms that do appear are often vague and easily mistaken for other, less serious conditions—such as digestive issues, fatigue, or normal aging. Approximately 60% of patients are already at Stage 4 by the time they receive a correct diagnosis, largely due to this diagnostic delay.

What is the difference between functional and non-functional neuroendocrine tumors?

Functional neuroendocrine tumors release hormones that cause noticeable hormone-related symptoms such as flushing, diarrhea, or changes in blood sugar levels. Non-functional tumors don’t release enough hormones to cause symptoms, though they can still cause problems if they grow large enough to impact nearby organs. About half of all neuroendocrine tumors are non-functioning, meaning patients don’t experience hormone-related symptoms.

Can neuroendocrine tumors be inherited?

While most neuroendocrine tumors occur sporadically, some individuals have a genetic predisposition due to inherited syndromes. The most important include Multiple Endocrine Neoplasia types 1 and 2 (MEN1 and MEN2), Von Hippel-Lindau syndrome, and Neurofibromatosis Type 1. People with these genetic conditions have a higher risk of developing neuroendocrine tumors and may benefit from genetic counseling and regular screening.

Why is the liver such a common site for neuroendocrine cancer metastasis?

The liver is particularly vulnerable to metastasis from neuroendocrine tumors, especially those originating in the gastrointestinal tract. This occurs because blood from the digestive system flows directly to the liver through the portal vein system before reaching the rest of the body. When cancer cells break away from tumors in the digestive tract and enter the bloodstream, they often get trapped in the liver’s filtering system, where they can establish new tumors. More than 50% of patients with certain types of pancreatic neuroendocrine tumors already have liver metastases at diagnosis.

What is carcinoid syndrome and when does it occur?

Carcinoid syndrome is a collection of symptoms that can occur when neuroendocrine tumors release certain hormones and chemical substances directly into the bloodstream. Common symptoms include facial flushing, diarrhea, wheezing, and sometimes rapid heartbeat. This syndrome typically develops when tumors have spread to the liver or other parts of the body, allowing hormones to bypass normal processing and enter the general circulation. Not all patients with metastatic neuroendocrine cancer develop carcinoid syndrome.

🎯 Key takeaways

  • Metastatic neuroendocrine cancer spreads most commonly to the liver, lungs, and lymph nodes through the bloodstream or lymphatic system
  • These rare cancers affect about 6 in 100,000 people worldwide, with most diagnoses occurring between ages 50 and 60
  • A staggering 60% of neuroendocrine tumor patients are already at Stage 4 when correctly diagnosed due to vague symptoms and delayed recognition
  • Inherited genetic syndromes like Multiple Endocrine Neoplasia (MEN1 and MEN2) significantly increase the risk of developing these tumors
  • Many neuroendocrine tumors grow slowly, often developing silently for years before causing symptoms that prompt medical attention
  • Symptoms vary widely depending on tumor location and whether the tumor produces hormones, ranging from fatigue and weight loss to hormone-related effects like flushing and blood sugar changes
  • Each patient’s experience with neuroendocrine cancer is unique—like zebra stripes, no two cases are exactly alike, earning these tumors the nickname “zebra cancers”
  • Early awareness of symptoms and prompt medical evaluation may help catch these tumors before extensive metastasis occurs, potentially improving treatment outcomes